Research ExplorerPublicationsRisk perception in natalizumab-treated multiple sclerosis pa...

Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists.

Standard

Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. / Heesen, Christoph; Kleiter, Ingo; Nguyen, Franziska; Schäffler, Nina; Kasper, Jürgen; Köpke, Sascha; Gaissmaier, Wolfgang.

In: MULT SCLER J, Vol. 16, No. 12, 12, 2010, p. 1507-1512.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Heesen, C, Kleiter, I, Nguyen, F, Schäffler, N, Kasper, J, Köpke, S & Gaissmaier, W 2010, 'Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists.', MULT SCLER J, vol. 16, no. 12, 12, pp. 1507-1512. <http://www.ncbi.nlm.nih.gov/pubmed/20826527?dopt=Citation>

APA

Heesen, C., Kleiter, I., Nguyen, F., Schäffler, N., Kasper, J., Köpke, S., & Gaissmaier, W. (2010). Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. MULT SCLER J, 16(12), 1507-1512. [12]. http://www.ncbi.nlm.nih.gov/pubmed/20826527?dopt=Citation

Vancouver

Heesen C, Kleiter I, Nguyen F, Schäffler N, Kasper J, Köpke S et al. Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. MULT SCLER J. 2010;16(12):1507-1512. 12.

Bibtex

@article{32e25fe4d6a842db96b9b3cb7e98739b,
title = "Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists.",
abstract = "Natalizumab is associated with the potentially life-threatening side-effect progressive multifocal leukoencephalopathy (PML). Little is known about patients' and physicians' risk estimates and attitudes towards natalizumab treatment.",
author = "Christoph Heesen and Ingo Kleiter and Franziska Nguyen and Nina Sch{\"a}ffler and J{\"u}rgen Kasper and Sascha K{\"o}pke and Wolfgang Gaissmaier",
year = "2010",
language = "Deutsch",
volume = "16",
pages = "1507--1512",
journal = "MULT SCLER J",
issn = "1352-4585",
publisher = "SAGE Publications",
number = "12",

}

RIS

TY - JOUR

T1 - Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists.

AU - Heesen, Christoph

AU - Kleiter, Ingo

AU - Nguyen, Franziska

AU - Schäffler, Nina

AU - Kasper, Jürgen

AU - Köpke, Sascha

AU - Gaissmaier, Wolfgang

PY - 2010

Y1 - 2010

N2 - Natalizumab is associated with the potentially life-threatening side-effect progressive multifocal leukoencephalopathy (PML). Little is known about patients' and physicians' risk estimates and attitudes towards natalizumab treatment.

AB - Natalizumab is associated with the potentially life-threatening side-effect progressive multifocal leukoencephalopathy (PML). Little is known about patients' and physicians' risk estimates and attitudes towards natalizumab treatment.

M3 - SCORING: Zeitschriftenaufsatz

VL - 16

SP - 1507

EP - 1512

JO - MULT SCLER J

JF - MULT SCLER J

SN - 1352-4585

IS - 12

M1 - 12

ER -